PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of apmJournal's HomeManuscript SubmissionAims and ScopeAuthor GuidelinesEditorial BoardHome
 
Adv Prev Med. 2012; 2012: 365980.
Published online Sep 29, 2011. doi:  10.1155/2012/365980
PMCID: PMC3182760
The Role of Immune Correlates and Surrogate Markers in the Development of Vaccines and Immunotherapies for Plague
E. D. Williamson *
Biomedical Sciences Department, Defence Science & Technology Laboratory, Porton Down, Salisbury Wilts SP4 0JQ, UK
*E. D. Williamson: dewilliamson/at/dstl.gov.uk
Academic Editor: Phillip R. Pittman
Received June 7, 2011; Accepted August 8, 2011.
Abstract
One of the difficulties in developing countermeasures to biothreat agents is the challenge inherent in demonstrating their efficacy in man. Since the first publication of the Animal Rule by the FDA, there has been increased discussion of potential correlates of protection in animal models and their use to establish surrogate markers of efficacy in man. The latter need to be relatively easy to measure in assays that are at least qualified, if not validated, in order to derive a quantitative assessment of the clinical benefit conferred. The demonstration of safety and clinical benefit is essential to achieve regulatory approval for countermeasures for which clinical efficacy cannot be tested directly, as is the case for example, for biodefence vaccines. Plague is an ancient, serious infectious disease which is still endemic in regions of the modern world and is a potential biothreat agent. This paper discusses potential immune correlates of protection for plague, from which it may be possible to derive surrogate markers of efficacy, in order to predict the clinical efficacy of candidate prophylaxes and therapies.
Articles from Advances in Preventive Medicine are provided here courtesy of
Hindawi Publishing Corporation